News
Augtyro

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

News

Press Releases

Views & Analysis

Newsletters and Deep Dive
digital magazine

Webinars

Podcasts

Video

White Papers

Spotlight on
Life Sciences Industry Report Part 1 Download

Life Sciences Industry Report 2025

In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.

Debates & Insight
PMA 2015 2016
Sponsored

Pricing & Market Access Outlook 2015/2016 Edition

Pricing and market access (P&MA) are key issues for the pharma industry as healthcare budgets continue to tighten and the value of innovative drugs, particularly in areas of high unmet need

Event

Debates & Insight

Partner Content